Is this the next Gilead (will Vertex dominate in cystic fibrosis disease management — the way Gilead has — in the HIV space)? Who really knows. . .
I will say that this science team is one to bet on — I did; and I will, again.
From our long-time buddy Ed Silverman, special to Forbes, then (do go read it all):
. . . .The Phase II trial was crucial because Vertex has wanted to find a way to treat [a] different subset of cystic fibrosis patients with various genetic mutations, in this instance, a mutation called F508del that is also the most common. Kalydeco was approved for treating a less common mutation called G551D, which accounts for just 4 percent of cystic fibrosis patients (see this). So by indicating its combination treatment could successfully improve lung functioning, Vertex scored a big win.
As a result, analysts are quickly increasing their outlook for the biotech. For instance, Robyn Karnauskas of Deutsche Bank Deutsche Bank says the results greatly bolster the likelihood that Vertex will be able to treat most patients with the F508del mutation. Moreover, she adds, the results “increase the market size opportunity for (treating) other mutations,” as well, she wrote in an investor note. . . .
Do stay tuned. It could be the dawn of a new age in biotech — more generally. Wow.